Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

502 results about "RNA - Ribonucleic acid" patented technology

Medical Definition of Ribonucleic acid (RNA) Ribonucleic acid (RNA): A nucleic acid molecule similar to DNA but containing ribose rather than deoxyribose. RNA is formed upon a DNA template. There are several classes of RNA molecules.

Methods and compositions for RNAi mediated inhibition of gene expression in mammals

Methods and compositions are provided for modulating, e.g., reducing, coding sequence expression in mammals. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is administered to a non-embryonic mammal, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

MiRNA with cell corpuscule as vector and preparation research approach thereof and application

The invention discloses micro ribonucleic acids (microRNA, miRNA) carried by cell microparticles (Microparticle, MP), a method for preparing the same, and application thereof in the technical field of biotechnological pharmacy. The invention provides a combination of the micro ribonucleic acids for evaluating the physiological and / or pathological states of a participant, and the combination contains all the micro ribonucleic acids which exist stably in serum / plasma particles of the participant and are detectable. At the same time, the invention provides an experimental method for preparing the cell microparticles containing specific micro ribonucleic acids and using the cell microparticles to perform gene-level regulation and control as well as modification on other cells and tissues. The combination and the method can be used for detecting and treating various diseases, including the aspects of the diagnosis and the differential diagnosis of various tumors, various acute and chronic infectious diseases and other acute and chronic diseases, the prediction and the curative effect evaluation of the occurrences of disease complications and the recurrences of malignant diseases, as well as the active ingredient screening, the efficacy evaluation and the judicial authentication of drugs, the detection of prohibited drugs and the like; besides, the combination and the method have the advantages of wide detection pedigree, high sensitivity, low detection cost, convenient available material, easy storage of samples and the like.
Owner:NANJING UNIV

Method and apparatus for reading reporter labeled beads

Combinatorially-synthesized deoxyribonucleic acid (DNA) oligonucleotides attached to encoded beads that are hybridized to amplified and labeled genomic DNA or ribonucleic acid (RNA) are analyzed using a flow imaging system. Oligonucleotides and corresponding reporters are bound to the surfaces of a plurality of small beads such that different beads bear different oligo sequences. Each bead bears a unique optical signature comprising a predefined number of unique reporters, where each reporter comprises a predefined combination of different fluorochromes. The composite spectral signature in turn identifies the unique nucleotide sequence of its attached oligo chains. This optical signature is rapidly decoded using an imaging system to discriminate the different reporters attached to each bead in a flow in regard to color and spatial position on the bead.
Owner:AMNIS CORP

Cancer vaccines

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Owner:MODERNATX INC

Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
Owner:ARROWHEAD PHARMA INC

Pharmaceutical compositions for delivery of ribonucleic acid to a cell

What is disclosed is a pharmaceutical composition for administration of a double stranded ribonucleic acid (dsRNA) molecule to an animal, comprising the dsRNA molecule and a peptide, wherein the dsRNA molecule comprises about 10 to about 40 base pairs, wherein the peptide comprises about 5 to about 40 amino acids and consists of all or part of the amino acid sequence KGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQ (SEQ ID NO: 59), and wherein the peptide binds to the dsRNA molecule.
Owner:MDRNA

Immune modulatory activity of human ribonucleases

Human extracellular ribonucleases (RNases) are widely distributed in various organs and body fluids and together with other members of the mammalian RNase A superfamily. In addition to their RNase activity, several RNases have been shown to have special biological actions, i.e., antitumor, antiviral and angiogenic properties. However, the molecular mechanisms of such activities are unclear. Using protein microarrays amplified rolling circle amplification (RCA), we investigated the effects of EDN (Rnase 2), ECP (Rnase 3) and RNase 1 on leukocytes cytokine production. We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with different combinations of RNases and RNase inhibitors. Members of human ribonuclease family (such as Rnase 1, hEDN (Rnase 2) and Rnase 3) induced expression of certain sets of cytokines in human leukocytes, including ENA-78, EOT2, BLC, GDNF, 1309, IFN-alpha, IFN-gamma, IL-10, IL-12P40, IL-12p70, IL-13, IL-16, IL-18, IL-1beta, IL-1ra, IL-2Sra, IL-3, IL-6, IL-6sR, IL-7, IL-8, IP-10, MCP-1, MCP-2, MCP-3, MCSF, MIG, MDC, MIP-1alpha, MIP-1beta, MPIF-1, NAP-2, RANTES, sCD23, OSM, TARC, TNF-alpha, TNF-R1 and uPAR. Thus members of the Rnase superfamily are therapeutic targets for treatment of inflammatory diseases and clinical conditions. Inhibition or augmentation of Rnase expression is used to modulate the immune system and is beneficial for host defense against various diseases and is exploited as an adjuvant. The expression of Rnases is a diagnostic marker for inflammation related conditions and is used to determine various disease stages. In addition, expression of cytokines, chemokines, growth factors is used to monitor efficacy of Rnase-base therapies.
Owner:PATHWAY DIAGNOSTICS CORP INC

Molecular and bioinformatics methods for direct sequencing

The present invention relates to methods for preparing an isolated biological sample containing at least one of DNA and RNA, such that the DNA and/or RNA is preserved in the sample at ambient temperatures for at least thirty days, the method comprising: contacting the isolated biological sample with a composition comprising a chaotropic agent, and subjecting the contacted sample to microbial cell lysis; and optionally, contacting the lysed biological sample with a slurry of size-selected silicon dioxide to form at least one of DNA-silicon dioxide complexes or RNA-silicon dioxide complexes in the sample; isolating at least one of DNA-silicon dioxide complexes or RNA-silicon dioxide complexes from the sample; and, separating at least one of DNA and RNA from the silicon dioxide and collecting at least one of the DNA and RNA.
The present invention further relates to methods for preparing an isolated biological sample, the method comprising, separating the components in an isolated biological sample according to their size, wherein the components are at least one of DNA and RNA; purifying and isolating SSU rRNA from the biological sample using a composition comprising a ribonuclease inhibitor and a deoxyribonuclease to remove DNA from the sample, reverse transcribing the SSU rRNA into ds cDNA using random primers for SSU rRNA.
The present invention also relates to computer implemented methods comprising, receiving an isolated sample prepared according to the methods of the invention, sequencing the sample, and providing the sequence with a sequence identifier (ID), the sequence comprising a plurality of groups of k-mers, each group of k-mers defining a node in a multi-level hierarchy which defines the relationship between the groups of k-mers; providing each group of k-mers with a respective group identifier (ID), determining the frequency of the k-mers in each group; generating a group signature array for each group of k-mers, each group signature array comprising the k-mers in each group that have the most increased frequency compared with the sibling k-mers; generating a signature map comprising each group signature array and at least one of the identifiers, the identifier of at least one parent group and the identifier of at least one child group; and outputting the signature map to be used to classify the sequence.
Owner:16S TECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products